UnitedHealth Group Stock Rises on Prior-Authorization Cuts and Earnings Guidance
UnitedHealth Group's stock price has surged in recent months, reaching nearly $400 per share as of September 4, 2026. This growth can be attributed to several factors, including the company's prior-authorization cuts and earnings guidance. According to a recent report, UnitedHealth Group has outlined plans to trim prior authorization demands by around 30 percent across various services starting October 1, 2026.
The company reported earnings per share of $6.38 for its latest quarterly report in mid-July 2026, significantly above the consensus estimate of $4.94. This positive surprise helped restore confidence in the stock and contributed to its upward momentum.
UnitedHealth Group's revenue also exceeded analyst expectations, generating $112.03 billion versus a projected $110.81 billion. The company delivered modest year-over-year growth of 0.4 percent compared to the prior year period.
The sell-side consensus for UnitedHealth Group's fiscal year 2026 earnings outlook is centered at approximately $19.82 per share, implying around 21.2 percent earnings growth versus the previous year. Analyst targets and valuation context also suggest that the stock has significant upside potential, with an average target price of around $456.56.